Here are three things to know.
1. The agency approved Erleada to treat nonmetastatic prostate cancer that does not respond to hormone therapy.
2. Erleada represents the first FDA-approved treatment for this form of cancer.
3. In a recent clinical trial of 1,207 prostate cancer patients, Erleada reduced the risk of distant metastasis or death by 72 percent compared to a placebo.
4. Erleada’s list price will be about $10,920 per month, according to Reuters.
More articles on supply chain:
FDA greenlights Teligent’s topical steroid: 3 things to know
8 initiatives FDA would pursue under FY 2018 budget
FDA clears seizure-monitoring smartwatch
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
